Article

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United States

2022-04-03

Abstract excerpt

<h4>Background</h4> In the United States (US), three vaccines are currently available for primary vaccination and booster doses to prevent coronavirus disease 2019 (COVID-19), including the 2-dose messenger ribonucleic acid (mRNA) BNT162b2 (COMIRNATY®, Pfizer Inc) and mRNA-1273 (SPIKEVAX®, Moderna Inc) vaccines, which are preferred by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Imm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 827adb98-45a7-5855-a85b-0b8bd97c3858
DOI: 10.1101/2022.03.31.22272957

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United StatesDOI 10.1101/2022.03.31.22272957Read

Modeling the Anticipated Public Health Benefits of the Next-Generation COVID-19 mRNA-1283 vaccine: An Interim U.S. Population-Level Impact AssessmentSemantic proximity Read

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity Read

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity Read

Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 vaccine in the United StatesSemantic proximity Read

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity Read

Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United StatesSemantic proximity Read

Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity Read

Effectiveness of the 2023–2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19–related Hospitalizations and Medical Encounters Among Adults in the United StatesSemantic proximity Read

Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity Read

COVID‐19 Vaccine Efficacy and the Evidence on BoostersSemantic proximity Read

The Potential Clinical and Economic Impact of the Next-Generation COVID-19 mRNA-1283 Vaccine in CanadaSemantic proximity Read

Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta DominanceSemantic proximity Read